Product News from the 04/07/06 News Brief
Astellas, Japan’s third-largest drug maker, has agreed to buy worldwide rights to Biogen Idec’s Amevive psoriasis drug for $60 million.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.